GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline

GSK is pursuing a focused oncology expansion across hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer. The strategy combines internal R&D with business-development activity, signaling continued investment in oncology growth but providing no financial targets, deal terms or near-term catalysts.